Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease.
Phase of Trial: Phase I
Latest Information Update: 04 May 2010
At a glance
- Drugs Mercaptopurine (Primary)
- Indications Crohn's disease
- Focus Pharmacokinetics
- 04 May 2010 Results have been presented at DDW 2010.
- 31 Mar 2010 Company added as trial sponsor, affiliate as reported by ClinicalTrials.gov.
- 14 Oct 2009 New trial record.